Jozef Arnout
Impact in
- Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management
- Hematology top 1%
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
Papers in
- Hematology 29
- Platelet Disorders and Treatments 19
- Blood Coagulation and Thrombosis Mechanisms 5
-
- Venous Thromboembolism Diagnosis and Management 9
- Co-authors
- Hans DeckmynJ. VermylenJos VermylenJean Marie StassenM. VanrusseltR. DemeyerePaul StrengersPaul Holvoet
- Journals
- Thrombosis and Haemostasis (21 papers)Lupus (3 papers)Journal of Thrombosis and Haemostasis (3 papers)Journal of Hypertension (2 papers)Circulation (2 papers)
- Partner nations
- BelgiumUnited KingdomNetherlands
In The Last Decade
Jozef Arnout
75 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 116
- Internal Medicine 223
- Hematology 660
- Rheumatology 536
- Biochemistry 150
- Critical Care and Intensive Care Medicine 114
Countries citing papers authored by Jozef Arnout
This map shows the geographic impact of Jozef Arnout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jozef Arnout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jozef Arnout more than expected).
Fields of papers citing papers by Jozef Arnout
This network shows the impact of papers produced by Jozef Arnout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jozef Arnout. The network helps show where Jozef Arnout may publish in the future.
Co-authors
The 25 scholars most cited alongside Jozef Arnout, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 137 | |
| 2 | 2008 | 72 | |
| 3 | 2004 | 128 | |
| 4 | Dietary habit profile in European communities with different risk of myocardial infarction: the impact of migration as a model of gene-environment interaction. The IMMIDIET Study. | 2001 | 30 |
| 5 | Pharmacodynamics and pharmacokinetics of RWJ-53308, a nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men | 1998 | 1 |
| 6 | A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor | 1997 | 3 |
| 7 | 1997 | 4 | |
| 8 | A murine monoclonal-antibody against vonwillebrand-factor (vwf) increases vwf binding to human platelet glycoprotein (gp) ib and gp iib/iiia | 1991 | 2 |
| 9 | TCV-309 - A NOVEL PAF-ANTAGONIST, INHIBITS PAF-INDUCED HUMAN PLATELET-AGGREGATION EXVIVO | 1991 | 1 |
| 10 | Measurement of vonwillebrand-factor antigen in plasma and platelets with an enzyme-linked-immunosorbent-assay based on 2 murine monoclonal-antibodies | 1991 | 1 |
| 11 | Commercially available intravenous immunoglobulins (iv igs) inhibit binding of anti-glycoprotein (gp)iib-iiia antibodies to their antigens in chronic idiopathic thrombocytopenic purpura (itp) patients | 1991 | 1 |
| 12 | Pilot-study of combined administration of ridogrel and alteplase in patients with acute myocardial-infarction | 1991 | 4 |
| 13 | An easy method to detect patients with vonwillebrand-factor defective in fviii-binding | 1991 | 1 |
| 14 | Synergistic effect of udcg212, a phosphodiesterase inhibitor (pde-i), and r68070, a combined thromboxane receptor antagonist (tra) and thromboxane synthase inhibitor (tsi), on platelet camp levels | 1989 | 2 |
| 15 | Thromboembolic complications and hemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients | 1985 | 4 |
| 16 | Udcg 115 and 212, 2 benzimidazo-pyridazinones with broad-spectrum antiplatelet activity | 1985 | 8 |
| 17 | Influence of the prostacyclin regulating plasma factor on human vascular endothelium in a microcirculation model | 1985 | 3 |
| 18 | Platelets activated locally in vivo regulate prostacyclin production by vessel wall | 1985 | 2 |
| 19 | Blood changes and enhanced thromboxane-b2 and 6-keto prostaglandin production in acute plasmodium-bergei infection in hamsters | 1983 | 2 |
| 20 | Dipyridamole inhibits platelet-aggregation in whole-blood invitro and exvivo | 1983 | 2 |
About Jozef Arnout
Jozef Arnout is a scholar working on Hematology, Internal Medicine, Rheumatology, Cardiology and Cardiovascular Medicine and Nephrology, having authored 78 papers that have together received 2.3k indexed citations. Recurring topics across this work include Platelet Disorders and Treatments (19 papers), Systemic Lupus Erythematosus Research (14 papers), Venous Thromboembolism Diagnosis and Management (9 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers), Heparin-Induced Thrombocytopenia and Thrombosis (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Atrial Fibrillation Management and Outcomes (5 papers) and Blood Coagulation and Thrombosis Mechanisms (5 papers). The work is most often cited by research in Internal Medicine (223 citations), Hematology (660 citations), Rheumatology (536 citations), Biochemistry (150 citations) and Critical Care and Intensive Care Medicine (114 citations). Jozef Arnout has collaborated with scholars based in Belgium, United Kingdom and Netherlands. Frequent co-authors include Hans Deckmyn, J. Vermylen, Jos Vermylen, Jean Marie Stassen, M. Vanrusselt, R. Demeyere, Paul Strengers, Paul Holvoet, Paolo Gresele and Francesco P. Cappuccio. Their work appears in journals such as Thrombosis and Haemostasis, Lupus, Journal of Thrombosis and Haemostasis, Journal of Hypertension and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.